Eton Pharmaceuticals (NASDAQ:ETON) Director Jennifer Mckie Adams Sells 50,000 Shares

Posted by George Bondi on Jun 17th, 2026

Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Free Report) Director Jennifer Mckie Adams sold 50,000 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total value of $1,624,000.00. Following the completion of the transaction, the director owned 50,000 shares in the company, valued at $1,624,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Eton Pharmaceuticals Price Performance

NASDAQ:ETON traded up $0.41 during mid-day trading on Wednesday, reaching $32.76. The stock had a trading volume of 341,840 shares, compared to its average volume of 356,477. The stock has a 50-day simple moving average of $28.65 and a two-hundred day simple moving average of $21.36. The stock has a market capitalization of $897.36 million, a PE ratio of -467.93 and a beta of 0.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88. Eton Pharmaceuticals, Inc. has a 12 month low of $13.09 and a 12 month high of $35.66.

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). The company had revenue of $24.27 million during the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. On average, equities analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on ETON shares. Craig Hallum upped their price target on Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, March 20th. B. Riley Financial upped their target price on Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a report on Friday, March 20th. Wall Street Zen upgraded Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. HC Wainwright upped their target price on Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a report on Friday, May 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Eton Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $41.00.

Read Our Latest Stock Report on Eton Pharmaceuticals

Institutional Investors Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Opaleye Management Inc. boosted its position in shares of Eton Pharmaceuticals by 0.3% during the 2nd quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock valued at $40,755,000 after purchasing an additional 7,930 shares in the last quarter. EcoR1 Capital LLC boosted its holdings in shares of Eton Pharmaceuticals by 7.0% during the 1st quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock worth $53,603,000 after buying an additional 141,394 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Eton Pharmaceuticals by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock worth $29,208,000 after buying an additional 31,942 shares in the last quarter. State Street Corp boosted its holdings in shares of Eton Pharmaceuticals by 14.5% during the 4th quarter. State Street Corp now owns 501,925 shares of the company’s stock worth $8,488,000 after buying an additional 63,480 shares in the last quarter. Finally, Cannell Capital LLC boosted its holdings in shares of Eton Pharmaceuticals by 17.3% during the 3rd quarter. Cannell Capital LLC now owns 455,405 shares of the company’s stock worth $9,896,000 after buying an additional 67,230 shares in the last quarter. Institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

(Get Free Report)

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.